The International Agency for Research on Cancer considers a beverage "very hot" if it is above 65°C, and says it is “probably carcinogenic” to people.

The International Agency for Research on Cancer considers a beverage "very hot" if it is above 65°C, and says it is “probably carcinogenic” to people.

The European Commission has put forward the European Radioisotope Valley Initiative (C/2026/6132) a new strategic framework to strengthen Europe’s leadership in the production of medical radioisotopes. It aims to reinforce EU security of radioisotope supply, guiding investment in the sector and reducing strategic dependencies on third countries, in particular Russia.  

With more than 10 million medical procedures using radioisotopes performed in the EU every year, mainly in oncology and cardiology, an impressive EU-wide production and distribution network has been developed to supply radioisotopes to patients across Europe daily. The EU has become the world’s leading producer of medical radioisotopes, exporting about half of its production overseas. However, critical parts of the European supply chain are exposed to dependencies on foreign suppliers, ageing production facilities, and competition from alternative suppliers, thereby creating the risk of investment displacement and higher costs. Furthermore, the global demand for medical radioisotopes, as well as the pace of innovation in this area, are increasing. Today’s ERVI communication responds to these challenges by defining a coordinated approach to supporting investments in research and development, bringing innovation to market, addressing value chain dependencies, and increasing production capacity. It also provides a direct contribution to the REPowerEU Roadmap towards ending Russian energy imports.

The Communication establishes five strategic priorities and 10 actions.

Research & Development and bringing innovations to market

The Commission will support research and innovation into the next-generation medical radioisotopes, radiopharmaceuticals and production technologies. A Strategic Research and Innovation Agenda (SRIA) - as used in other sectors - will help better connect research with market needs and patients. Instruments such as the emerging IPCEI for innovative nuclear technologies, the European Innovation Council, and new European partnerships can help mobilize public and private investment to accelerate innovation deployment. 

Investments in production facilities to ensure security of supply

The initiative aims to guide and support Member States and industry investments across the medical radioisotope value chain to strengthen the resilience and localisation of EU supply. Priorities include the development of EU-based metallic High Assay Low Enriched Uranium (HALEU) capacity and production of stable isotopes currently imported from Russia, as well as upgrades of existing reactors and construction of new production facilities. Member states should make use of the EU Startup and Scaleup Strategy, the SGEI State aid framework and the recent Critical Medicines Act for which the political agreement was achieved this year to support these efforts, while the Commission will explore ways to better combine public and private financing.

Market Monitoring and Forecasting

The Commission will act to improve the visibility of supply and demand trends and assess the investment needs of the European market for radioisotopes. This work will build upon the European Observatory on the Supply of Medical Radioisotopes and rely on continuing involvement of Member States and stakeholders, while making full use of the new EU mechanisms for tackling shortages of essential medicines.

Developing strategic international partnerships

ERVI will support cooperation with trusted international partners to diversify supply chains, strengthen resilience and promote scientific and industrial collaboration. In particular, the continuing cooperation with our partners in the UK and US is crucial for developing a resilient supply chain for metallic High Assay Low Enriched Uranium (HALEU).

Supporting an evolving regulatory framework

The Commission will cooperate with the International Atomic Energy Agency to support reliable international transport of medical radioisotopes and explore further measures to facilitate transport between Member States. A further step will be to pursue the streamlining of EU and national procedures for radiation protection and waste management in nuclear medicine to support patients’ access to innovative treatments.

Background

In June 2024, the Council called on the Commission to seek to maintain Europe’s global leadership role in the supply of medical radioisotopes and make tangible and swift progress on developing ambitious ‘building blocks’ for specific actions. 

In order to define the objectives and architecture of ERVI, the Commission carried out extensive consultations involving stakeholders and member states and published a feasibility study in March 2026.

The initiative also builds on the Strategic Agenda for Medical Ionising Radiation Applications (SAMIRA), adopted by the Commission in 2021 to strengthen the secure supply of medical radioisotopes, improve quality and safety in radiation medicine, and support innovation in nuclear medicine technologies.

In May 2025, the REPowerEU road map further highlighted the need to increase EU production capacities, reduce dependency on Russia and strengthen the resilience of the European medical radioisotope supply chain. The establishment of ERVI was identified as one of the roadmap’s key actions.

Related links

• Communication on the European Radioisotope Valley Initiative (C/2026/6132)
• European Radioisotope Valley Initiative
• ERVI feasibility study
• SAMIRA – Strategic Agenda for Medical Ionising Radiation Applications
• European Observatory on the Supply of Medical Radioisotopes

From illicit production to smuggling, the illicit tobacco trade continues to pose a serious problem for the EU, as it negatively impacts its finances, public health and security, according to a new report by the European Court of Auditors (ECA). Although the European Commission and EU countries have made efforts to combat this global criminal phenomenon, their action is not robust enough. Illicit production across the EU is increasing, smuggling methods are getting more sophisticated, and new tobacco products are on the rise. Against this backdrop, the auditors criticise poor cross-country cooperation, which suffers from persistent gaps and lacks a concerted EU-wide approach.

The illicit tobacco trade has changed significantly in recent years. Organised crime groups have strategically relocated production from Ukraine to the EU in order to shorten supply chains and access consumers more directly. Although smuggling remains a problem, illicit manufacturing sites have been detected in almost all EU countries, and illicit production has grown across the EU. For instance, in a large-scale illicit cigarette production factory in Belgium, each machine was capable of producing around a million cigarettes per hour. In the largest illicit cigarette factory dismantled in Spain, three million packets of counterfeit cigarettes were seized, i.e. 56 times the height of Mount Everest if the cigarettes were stacked horizontally.

“The EU cannot afford to let its fight against the scourge of illicit tobacco go up in smoke,” said Petri Sarvamaa, the ECA Member leading the audit. “If we are serious about safeguarding citizens’ health, wallets and security, the Commission and member states must up their game to fight criminal activity head-on.”

The illicit tobacco trade deprives EU and member state budgets of €13 billion a year, according to the Commission’s estimate. However, this figure should be treated with caution, as it is based on external studies. The fact remains that the Commission lacks a reliable and independent EU-wide estimate of the illicit tobacco market, its structure and its economic impact, e.g. in terms of lost tax revenues. Such data, however, are crucial for determining the magnitude of the problem and designing an effective response. As it stands, the Commission’s reporting is largely based on seizures, and so does not provide a full picture of the situation.

Over the past decade, the EU and its member states have taken measures to combat the illicit tobacco trade. However, EU law is not harmonised, and member states’ efforts are uneven. For example, key production inputs such as raw tobacco and production machinery, and new types of products such as heated tobacco products and liquids for e-cigarettes, are not treated in the same way across the EU. At the same time, the EU regulatory framework gives member states a free hand in choosing counter-measures, thus leading to enforcement gaps that organised crime groups can exploit. In particular, as national control systems and enforcement approaches differ, such as in the definition of offences and the severity of penalties, this can encourage criminal activities to relocate to laxer jurisdictions. Furthermore, EU countries are inconsistent in the way they exchange information.

In the EU, responsibility for combating the illicit tobacco trade is shared between several stakeholders. However, no single entity has a clear coordinating role, meaning that initiatives are fragmented. The auditors thus call on the Commission to assume a more active role in combating the illicit trade in tobacco products.

Background information

Although overall tobacco consumption has continued to fall, the quantity of illicit tobacco products in the EU has risen in recent years. In 2023, the Commission estimated that the quantity of illicit tobacco products was 8.8 % of total cigarette consumption. Excluding cigarettes, the illicit tobacco market amounts to nearly 21 000 tonnes in the EU. According to estimates, these new products make up 13 % of the market value of tobacco products sold in the EU, and attract younger consumers.

Illicit tobacco products are very attractive for organised crime groups due to their high profitability and comparatively low risk (penalties have traditionally been light and detection rates low). Such illegal activity not only provides a significant source of income for criminals but, by offering cheaper tobacco products, also undermines efforts to reduce tobacco consumption. Ultimately, it leads to losses in terms of customs duties, value-added tax and national excise duties.

The audit assesses the effectiveness of the action taken by the Commission and the member states. The auditors carried out field visits in Belgium, Spain, Poland and Romania, and include examples of illicit manufacturing sites in their report. ECA special report 23/2026 “Combating the illicit trade in tobacco in the EU: Fragmented efforts and persistent gaps” is available in 24 EU languages on the ECA website.

This year has proved that the era of the strongman is undoubtedly upon us. Littered throughout the highest offices across government and international organisations, they have proved time and again that due process is for suckers and that you, too, can bribe your way to the desired outcome.

Take Gianni Infantino who is seeking to sell off 20% of the world’s most cherished football tournament. He, like Trump, has dug in his heels, choosing to strategically dole out favours, and then use their power to pit people against each other, rather than following the rules. Having leveraged their positions to fulfil their agenda, no matter the cost, they deny anything they don’t wish to confront, deflect questions they don’t like, and gaslight anyone who dares to call them out.

Whilst Infantino and Trump have dominated headlines of late, the actions of the world’s health agency head have - despite years of alarm bells - received comparatively little scrutiny; a concern when you consider how instrumental effective healthcare is to our everyday lives.

Like Infantino, Dr Tedros wedges countries and leaders apart in order to defy institutional processes and push through his agenda. In 2025, Dr Tedros pared down his leadership team by nearly 30%. Most recently, the WHO’s top scientist, Dr Jeremy Farrar, was replaced with a highly “controversial” and apparent confidant of Dr Tedros. The pattern of replacing officials with faithful advisers is a classic move of the strongman and underlines how institutional structures can be leveraged to advance personal aims.

One of those aims appears to be purging WHO of those who challenge the opaque bureaucratic functions that Dr Tedros oversees. Dr Farrar’s surprise resignation was said to have been due to increasing frustrations with the WHO’s internal politics. Curiously, in an all-staff email, Dr Tedros reframed Dr Farrar’s departure as a retirement and, in communications with the press, the organisation refused to comment on

r’s relationship with (read: criticisms of) the WHO. 

Now, Dr Tedros is allegedly bulldozing through the replacement of the WHO’s Regional Director for its South-East Asia Regional Office (SEARO), Saima Wazed. Ms Wazed has been on administrative leave for over a year following unfounded allegations made against her by Bangladesh’s Interim Government. As the nation roiled under an intense period of political unrest, Ms Wazed was falsely accused of absconding from the country when, in reality, she was stationed in New Delhi, acting in her capacity as the SEARO Regional Director. The WHO knew this but put her on administrative leave without pay anyways. In that time other, unfounded allegations bubbled up, including claims Ms Wazed requested reimbursement from WHO for personal travel to China, which, it would appear, was an entirely fabricated allegation.

The WHO’s handling of Ms Wazed’s leave has been deeply flawed and discussed at length by top-level jurists and a UN Special Rapporteur. Since the allegations were made, a new Bangladeshi government has been elected and two of WHO’s Officers-in-Charge have been appointed to “temporarily” oversee the SEARO. Still, no information about the veracity of the allegations against Ms Wazed have been made public despite the fact that WHO’s own guidelines explicitly say that administrative leave is not a punishment. If allegations are not verified in a reasonable timeframe, WHO has a duty to end the leave.

For her part, Ms Wazed has called for an investigation into Dr Tedros, alleging that he or his office leaked confidential documents, provided false or misleading information to Member States, and breached confidentiality requirements and the WHO’s Code of Conduct by directly engaging with the former government of Bangladesh.

While the WHO has the responsibility to investigate allegations against its staff, claims from a national authority should not automatically be treated as proven fact for a supposedly apolitical organisation. It has now been over a year since Ms Wazed was put on leave. This, combined with the absence of any apparent independent investigation into the allegations points to a fast and loose approach to proper administrative processes, one in which the attempt to hold Ms Wazed in administrative purgatory exists as a vehicle to quietly remove her from the organisation.

Just as Infantino is leveraging greater funding for African nations to gather support for his upcoming presidential bid, Dr Tedros is using what amounts to an uncosted holiday jaunt to the South Pacific to bring a forced-end to this saga. Reports suggest that the Director General is directing SEARO nations to do away with due processes and install Ms Wazed’s successor. For their trouble, fielty, and feigned ignorance to standard administrative practices, Dr Tedros is organising a regional meeting, spending at least €163k to fly in the SEARO directors and staff for a face-to-face meeting in Timor Leste. Despite years of cutting the WHO to the bone and a record budget shortfall, for Dr Tedros no expense is too great to push through his agenda.

Ultimately, this is a clear attempt by Dr Tedros to circumvent proper levels of scrutiny about this crucial decision, and to hide his undermining of the WHO’s standard procedures by sweetening the deal for other regional staff. Pulling directly from the Infantino playbook, Dr Tedros has escaped public outcry which would hold him responsible. But his treatment of Saima Wazed, what many would call an organised witch-hunt, should concern us all, as yet another international organisation sees the erosion of due processes.

Advocate General Juliane Kokott has published her opinion calling on the EU’s top court to invalidate provisions in the Urban Wastewater Treatment Directive requiring pharmaceutical and cosmetics companies to fund at least 80% of the cost of removing micropollutants from urban wastewater.

“Today’s opinion strengthens the case for stopping the clock on this Directive to avoid consequences for the availability of medicines for patients,” said Director General of Medicines for Europe, Adrian van den Hoven. “The Commission should use this opportunity to properly review the EPR scheme before companies are forced to make decisions that could affect medicine supply or health security.”

The opinion, issued in response to a Polish challenge to the Directive, is not binding on the Court of Justice of the European Union, but it appears to support criticisms that industry has long made about the evidence and proportionality underpinning the extended producer responsibility (EPR) scheme.

Generic and biosimilar companies say those concerns are already affecting investment decisions. Manufacturers must plan production years ahead.

MEPs are pushing for an EU solidarity mechanism to help patients pay for treatment abroad, arguing that financial barriers are preventing Europeans from exercising rights they have had on paper for more than a decade.

The calls came as Parliament discussed a report commissioned to inform its own-initiative report on modernising patients’ rights in cross-border healthcare. The study found that cross-border care accounts for just 0.004% of EU public health expenditure, despite patients continuing to face upfront costs, complex reimbursement procedures and prior-authorisation requirements.

Tomislav Sokol (EPP, Croatia) called the proposed solidarity mechanism a potential “game changer” for vulnerable patients, but challenged Parliament to spell out how it would work.

“How would it work in practice? How would it be financed? Would this be part of the EU budget?” Sokol asked. “We need to know it now, so that we can also use this in negotiations on the future EU budget, in the next MFF.”

A fruitarian diet can provide fiber and antioxidants but may leave the body short of protein and essential nutrients.

The post What happens to your body when you eat only fruit? appeared first on BOL News.

Scientists find evidence that microscopic metal debris can reach the brain, while its long-term effects remain unclear.

The post What happens to joint implants over time? appeared first on BOL News.

The minister said a telemedicine center would be launched at PIMS to help reduce the burden of patients.

The post Mustafa Kamal reviews fire safety, cooling systems at PIMS appeared first on BOL News.

The database also supports Saudi Vision 2030, particularly its Health Sector Transformation Program.

The post Saudi Arabia launches first ‘National Food Composition Database’ to promote health appeared first on BOL News.

Running with Rachel Entrekin must be pretty wild—she encourages competitors and stops mid-race to pet dogs. But her personality is even bigger off the course. Tough and empathetic, her running success has come after 13 years of hard work and a battle to transform an addictive, perfectionist past into a healthier relationship with food, rest, and herself. And even as success came and ultramarathons were won, she watched opportunities go to her male competitors. Gloria Liu honors the incredible achievement of “smashing records while battling impostor syndrome and the fragility of your own self-worth in a world enamored with men, and their accomplishments.”

The key word, however, is average. As any female runner who’s ever passed a dude working himself into a froth to stay ahead of her on the trail knows, women beat men on an individual basis daily. And as athletes like Entrekin and Dauwalter have shown, they do so, occasionally and spectacularly, even at the elite level. We have an understandable reflex to point to categorical advantages that might explain why women can do this, Malcolm says: “It’s inherently feel good, the David and Goliath aspect of a woman winning outright.”

But in searching for the advantages we hope all women have, we may be missing a simpler truth: Most men are faster than most women, but some women still beat most men. The point is not that we have any advantage. The point is that they have almost every advantage—and we still win.

The concern is gaining attention as low-calorie sweeteners become increasingly common in food and drinks.

The post Common sweetener ‘Xylitol’ linked to cardiovascular and stroke risk appeared first on BOL News.

The US Food and Drug Administration’s (FDA) decision to allow 20 ZYN nicotine pouch products to carry a specific reduced-risk claim has created a striking contrast with the direction of European Union policy, as Brussels prepares new product rules and proposes EU-wide taxation of nicotine pouches.

The United States Food and Drug Administration has authorised 20 ZYN nicotine pouch products to be marketed with a statement informing adult smokers that completely replacing cigarettes with the pouches can reduce the risk of several serious diseases.

The decision, issued on 30 June 2026, represents the first time that the FDA has granted Modified Risk Tobacco Product orders to nicotine pouches.

The authorised wording states:

“Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.”

The orders cover ten varieties of ZYN, each sold in nicotine strengths of 3mg and 6mg. The products include Chill, Cinnamon, Citrus, Coffee, Cool Mint, Menthol, Peppermint, Smooth, Spearmint and Wintergreen.

The manufacturer, Swedish Match USA, is owned by Philip Morris International. The products had already received FDA authorisation to remain on the US market in January 2025, but the new decision goes considerably further by permitting a specific comparative health claim.

The FDA said its decision followed an extensive scientific review and was intended to give adult tobacco users accurate information about differences in risk between products.

“FDA’s review of modified risk products is intended to ensure that adult users have clear, science-based information about the relative harms of tobacco products, so they can make informed choices,” said Bret Koplow, acting director of the FDA’s Centre for Tobacco Products.

The ruling does not mean that ZYN is harmless, nor does it approve the products as medicines or smoking-cessation treatments. Nicotine is addictive, and the FDA continues to advise people who do not currently use tobacco or nicotine not to begin.

The significance of the decision lies instead in the regulator’s formal recognition that nicotine products can present very different levels of risk.

Switching, rather than dual use

A crucial qualification is contained in the phrase “instead of cigarettes”. The authorised claim applies to smokers who replace cigarettes with ZYN. It does not promise the same reduction in risk to consumers who use nicotine pouches while continuing to smoke.

Cigarettes burn tobacco, creating smoke containing toxic substances responsible for most smoking-related cancers, cardiovascular disease and respiratory illness. Nicotine pouches deliver nicotine through the lining of the mouth without burning tobacco or producing smoke.

This difference is central to the principle of tobacco harm reduction: smokers who cannot or do not wish to stop using nicotine may nevertheless reduce their health risks by moving away from combustible products.

The FDA’s decision therefore recognises an important distinction that is frequently blurred in political debate. A product can be addictive and unsuitable for non-users while still being substantially less dangerous than smoking.

UK-based public health commentator Clive Bates, a former director of Action on Smoking and Health, has argued that nicotine pouches could deliver benefits comparable to those associated with the use of Swedish snus in Scandinavia.

“Tobacco-free nicotine pouches with a consumer acceptable nicotine content have the potential to benefit public health in the same way that is documented for Swedish snus in Scandinavia, that is, by serving as a low-risk alternative to cigarettes”, Bates said.

“The European Commission should pay close attention to FDA’s exhaustive process and extensive reasoning. It’s unusual to have anything good to say about the Federal government these days, but this is an important exception, where the right answer has been reached for the right reasons”, he added.

Bates has also argued that poorly designed regulation, including excessively low nicotine limits, could make pouches less effective as substitutes for cigarettes and unintentionally protect the market for combustible tobacco.

Why the FDA decision matters for Europe

The American ruling comes at a particularly important moment for the European Union.

The European Commission is simultaneously advancing a formal proposal to overhaul tobacco taxation (TED) and preparing a broader revision of the EU legislation governing tobacco and nicotine products, their presentation, sale, advertising and promotion.

Nicotine pouches are not comprehensively regulated at EU level under the current Tobacco Products Directive (TPD). Because they contain nicotine but no tobacco, they fall outside many of the harmonised provisions that apply to cigarettes, roll-your-own tobacco, heated tobacco and electronic cigarettes. The result is a fragmented European market.

Some member states permit nicotine pouches subject to national restrictions. Others have introduced nicotine limits, packaging and warning requirements or advertising controls, while France has pursued a prohibition.

Different national rules create uncertainty for consumers and manufacturers and complicate enforcement across the EU’s internal market.

The Commission’s April 2026 evaluation of the European tobacco-control framework identified the rapid growth of nicotine pouches, electronic cigarettes and heated tobacco products as one of the main challenges that existing EU legislation is no longer adequately equipped to address.

The evaluation concluded that EU rules had contributed to falling smoking rates and smoking-related deaths but were failing to keep pace with changes in products, marketing practices and consumer behaviour.

The EC is particularly concerned about the use of novel nicotine products among children, adolescents and young adults. However, the FDA decision introduces an additional issue that EU policymakers will now find difficult to avoid: whether new EU rules should recognise differences in risk between combustible cigarettes and smoke-free nicotine products.

Two contrasting regulatory philosophies

The emerging difference between Washington and Brussels is not simply that one jurisdiction is permissive and the other restrictive.

The FDA subjects nicotine products to an exceptionally demanding premarket review. Products must receive authorisation before they can legally be marketed, and separate evidence is required before a manufacturer may make a modified-risk claim.

The FDA can impose marketing conditions, require post-market surveillance and withdraw an order if later evidence shows that the product no longer benefits public health.

Its approach nevertheless accepts that consumers should be told when credible evidence shows that completely switching from one product to another reduces disease risk.

The Commission’s current approach places greater emphasis on reducing the overall attractiveness and consumption of tobacco-related and nicotine products. Its taxation proposal explicitly presents nicotine pouches as products that can prolong addiction or act as substitutes for cigarettes, especially among young people.

These positions are not necessarily irreconcilable.

The EU could impose age controls, marketing restrictions, ingredient standards and proportionate nicotine limits while still recognising that adult smokers may benefit from switching completely away from cigarettes.

It could also prohibit unsubstantiated commercial claims while creating an evidence-based process through which manufacturers could apply for permission to communicate verified differences in risk.

The alternative would be to impose increasingly similar taxation, warnings and advertising rules on products with significantly different health consequences.

A test for evidence-based policymaking

The EC ran a public consultation on revisions to both the Tobacco Products Directive (TPD) and the Tobacco Advertising Directive (TAD) from 22 May to 14 August this year. The consultation, is intended to inform a revision of the legislative framework planned before the end of 2026.

It creates an opportunity to consider evidence that was not available when the current Tobacco Products Directive was adopted in 2014.

Nicotine pouches were then a marginal product. They now represent a rapidly expanding category, and national governments are adopting increasingly divergent responses.

The FDA decision does not compel Europe to follow the US model. The EU has different legal structures, public-health priorities and attitudes towards commercial nicotine.

It does, however, establish a significant regulatory precedent.

One of the world’s most influential public-health authorities has concluded that there is sufficient evidence to tell adult smokers that completely switching to specified nicotine pouches reduces their risk of mouth cancer, heart disease, lung cancer, stroke, emphysema and chronic bronchitis.

That finding sits uneasily with any policy or public communication suggesting that cigarettes and smoke-free nicotine products are essentially equivalent.

The issue is particularly relevant to the Commission’s tax proposal. Taxation affects consumer behaviour partly by changing the relative prices of products. If pouches are taxed so heavily that the economic advantage over cigarettes is substantially reduced, smokers may have less incentive to switch.

Conversely, setting taxes too low could increase affordability and use among young people who have never smoked.

The task for EU legislators is therefore not simply to choose between regulation and deregulation. It is to develop a framework that calibrates restrictions, taxation and consumer information according to evidence about risk, behaviour and population-level effects.

Europe’s choice

While Washington is recognising that adults deserve accurate information about lower-risk alternatives, Brussels is looking for ways to restrict, tax or ban them.

Meanwhile, the EU is failing to control illegal disposable vapes, banned flavours, excessive nicotine levels and unauthorised devices moving through black-market channels. Regulated products are demonised, while illegal and unregulated products keep reaching consumers, including young people.

The forthcoming EU debate will test whether Brussels can reconcile its tobacco-free objective with the potential role of lower-risk alternatives.

The FDA decision makes three points that are likely to shape that discussion.

First, nicotine pouches are not harmless and should not be promoted to children or people who do not use nicotine.

Second, the absence of combustion means that their risks can differ substantially from those associated with cigarettes.

Third, the greatest potential benefit arises when smokers switch completely rather than using pouches alongside continued smoking.

The Commission is right to address gaps in the existing legislation and fragmentation between member states. Common product standards, youth protections and enforcement rules may be necessary for the Single Market to function properly.

But regulation that fails to acknowledge relative risk could also have unintended consequences.

Clive Bates and other harm-reduction advocates argue that treating all nicotine products as though they are similarly dangerous can preserve smoking by discouraging consumers from moving to safer alternatives. European health campaigners respond that the growth of commercially marketed nicotine products could create a new generation of dependent users.

The revised Tobacco Products Directive (TPD) will need to address both concerns.

As the EC completes its consultation and develops its legislative proposal, the American decision gives European policymakers a concrete case study rather than a theoretical argument.

The question is no longer whether a regulator could authorise a carefully limited reduced-risk claim for a nicotine pouch. The FDA has now done so.

The question for Europe is whether its forthcoming legislation will allow comparable scientific evidence to influence regulation, taxation and communication — or whether nicotine pouches will be treated principally as another product to be restricted, irrespective of their potential role in moving smokers away from cigarettes.

China carries a major share of the global lung cancer burden.

The post Lung cancer deaths in China to reach 760,000 by 2030 appeared first on BOL News.

Drugs such as morphine and fentanyl act on opioid receptors throughout the body and central nervous system.

The post Scientists find brain switch that could help turn off chronic pain appeared first on BOL News.

Mounjaro was first approved by the FDA in 2022 for improving blood sugar control in adults with type 2 diabetes.

The post FDA approves Mounjaro to protect high-risk diabetes patients from heart risks appeared first on BOL News.

The extension means decisions on immigration and visa applications from residents of the Democratic Republic of Congo, Uganda and South Sudan will remain on hold until Sept. 28.